Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the Carlsbad, California-based developer of RNA-targeted medicines, announced on October 16, 2026, that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended expanding the European indication for TRYNGOLZA (olezarsen) to adults with severe hypertriglyceridemia. The proposed authorization would cover patients with fasting triglycerides of at least 880 mg/dL, equivalent to 10 mmol/L, as an adjunct to diet and in combination with other lipid-lowering treatments. The recommendation follows Phase 3 evidence showing reductions in fasting triglycerides of up to 72% compared with placebo and an 85% reduction in adjudicated acute pancreatitis events in a pooled analysis. The European Commission is expected to make its final decision during the fourth quarter of 2026.
The development comes four months after the United States Food and Drug Administration approved TRYNGOLZA for a broader severe hypertriglyceridemia population, beginning at triglyceride levels of 500 mg/dL. In Europe, the medicine is already authorized for adults with familial chylomicronemia syndrome, a rare inherited disorder associated with extremely elevated triglycerides. The latest CHMP opinion therefore concerns an extension of an existing European authorization rather than the introduction of an entirely unapproved medicine.
The distinction matters commercially because the proposed European population is substantially larger than the original familial chylomicronemia syndrome population. Ionis and its international commercialization partner, Swedish Orphan Biovitrum, commonly known as Sobi, estimate that approximately 700,000 people across the five largest European markets have triglyceride levels of at least 880 mg/dL. However, the CHMP recommendation is not the final legal authorization, and national reimbursement decisions would still influence practical access following any European Commission approval.
What exactly has the CHMP recommended for TRYNGOLZA in Europe?
The CHMP has recommended an extension of TRYNGOLZA’s existing marketing authorization to include adults with severe hypertriglyceridemia whose fasting triglyceride concentrations are at least 880 mg/dL. The proposed indication specifies use alongside dietary management and other lipid-lowering therapies. This positions olezarsen as an additional treatment for patients at substantial risk from persistently elevated triglycerides, rather than as a replacement for appropriate lifestyle and conventional medical care.
The recommendation must be considered by the European Commission before becoming an authorized indication throughout the European Union. Although positive CHMP opinions frequently precede European Commission approval, the two steps are legally distinct. The October announcement does not establish that patients across Europe can already receive olezarsen under the proposed expanded indication.
The proposed European threshold is also narrower than the corresponding United States indication. The FDA authorized olezarsen in June 2026 for adults with triglycerides of at least 500 mg/dL, including treatment to reduce triglyceride levels and the risk of acute pancreatitis. The European recommendation uses 880 mg/dL, identifying a population with more markedly elevated fasting triglycerides.
This difference has practical implications for patient eligibility and commercial scale. Patients whose triglyceride levels fall between 500 and 879 mg/dL may satisfy the United States indication but would not meet the newly proposed European threshold solely on the basis of their triglyceride measurement. The final European labeling will determine the precise authorized population.
How did the CORE and CORE2 Phase 3 trials support the recommendation?
The pivotal evidence came from two global, randomized, double-blind, placebo-controlled Phase 3 studies, CORE and CORE2, conducted with the TIMI Study Group. CORE enrolled 617 participants, while CORE2 enrolled 446, creating a combined study population of 1,063 patients. All participants had triglycerides of at least 500 mg/dL at enrollment and received background management consistent with standard care.
Participants were assigned to receive olezarsen at 50 mg or 80 mg, or placebo, through subcutaneous administration every four weeks for 12 months. The primary efficacy endpoint assessed the percentage change in fasting triglyceride levels from baseline to six months compared with placebo. Both trials achieved their primary endpoints, establishing significant triglyceride reductions across the investigated treatment regimens.
Ionis reported placebo-adjusted reductions ranging from approximately 49% to 63% with the 50 mg dose and from 55% to 72% with the 80 mg dose, depending on the trial and analysis. The maximum reported 72% reduction therefore represents the upper end of the trial findings, not the average reduction experienced by every treated patient. The company also reported that the triglyceride-lowering effect was maintained through 12 months.
Approximately 47% of CORE participants and 37% of CORE2 participants had fasting triglycerides of at least 880 mg/dL at baseline. This subgroup is particularly relevant to the proposed European indication because it reflects the threshold selected by the CHMP. The evidence supporting authorization consequently includes a broader severe hypertriglyceridemia population, with additional analyses focused on those with the highest triglyceride levels.
Why is the 85% reduction in acute pancreatitis events important?
Severe hypertriglyceridemia can cause acute pancreatitis, a potentially life-threatening inflammation of the pancreas. Episodes may involve severe abdominal pain, vomiting, hospitalization and complications affecting other organs. Patients who have already experienced pancreatitis can face additional risks from recurrent episodes.
Lowering triglycerides is an important treatment objective, but preventing clinically significant pancreatitis represents a more direct measure of patient benefit. In a pooled analysis of CORE and CORE2, Ionis reported an 85% relative reduction in adjudicated acute pancreatitis events over 12 months among olezarsen-treated patients compared with placebo. The result was statistically significant and contributed to the overall clinical evidence supporting the medicine.
An 85% relative reduction should not be confused with an 85-percentage-point absolute reduction in risk. The relative effect describes the rate of events compared with the control group, while the absolute benefit depends on how frequently pancreatitis would otherwise occur. The number of events, baseline risk and patient characteristics are therefore relevant when considering the expected benefit for an individual patient.
The pooled finding is especially important because many lipid-lowering trials focus predominantly on biochemical markers rather than directly measured clinical complications. Demonstrating fewer independently adjudicated pancreatitis events provides evidence that extends beyond laboratory triglyceride reductions. Nevertheless, the studies followed participants for approximately one year, and longer-term outcomes will remain important as commercial treatment experience expands.
What did the high-risk subgroup analysis establish?
A separate analysis presented during 2026 examined 455 patients whose baseline triglyceride levels were at least 880 mg/dL. This population more closely corresponds to the group covered by the proposed European indication. The analysis reported a placebo-adjusted triglyceride reduction of approximately 66% with olezarsen 80 mg and 59% with the 50 mg regimen after six months.
Approximately 85% of treated patients in the relevant analysis achieved triglyceride concentrations below 10 mmol/L. Crossing that threshold is clinically relevant because the proposed European population begins at or above the same concentration. However, reaching a laboratory threshold is not identical to eliminating the risk of future pancreatitis.
The subgroup evidence provides a more focused view of treatment activity among patients with particularly severe elevations. Such individuals may have persistent triglyceride concentrations despite lifestyle intervention and conventional medicines. Their baseline risk may therefore differ from that of patients with more moderate lipid abnormalities.
The results also reinforce the need to distinguish the full Phase 3 populations from the proposed European population. CORE and CORE2 enrolled patients beginning at 500 mg/dL, while the recommended European indication is restricted to those meeting the higher threshold. Findings from the complete trials provide important supporting evidence, but the subgroup analysis is particularly informative for assessing the proposed label.
How does olezarsen reduce triglycerides through apoC-III inhibition?
TRYNGOLZA is an antisense oligonucleotide medicine designed to reduce the production of apolipoprotein C-III, commonly abbreviated apoC-III. This protein is produced primarily in the liver and plays an important role in regulating triglyceride-rich lipoproteins in circulation. Elevated apoC-III activity can interfere with normal triglyceride metabolism and contribute to persistently high concentrations.
Olezarsen uses an RNA-targeted mechanism to reduce the messenger RNA responsible for producing apoC-III. By lowering synthesis of this regulatory protein, the treatment is intended to improve the clearance and handling of triglyceride-rich particles. The approach differs from conventional therapies that primarily influence cholesterol synthesis or other aspects of lipid metabolism.
The drug incorporates ligand technology intended to facilitate delivery to liver cells. This tissue-directed design helps concentrate the RNA-targeting effect in an organ central to lipoprotein production and metabolism. The treatment is administered through periodic subcutaneous injections rather than as a daily oral medicine.
However, substantial triglyceride reduction does not mean that the underlying causes of dyslipidemia have been permanently corrected. Patients may continue to have genetic predispositions, metabolic disease or other contributors to elevated triglycerides. Dietary management and monitoring therefore remain relevant throughout treatment.
The clinical significance of apoC-III inhibition is supported by the combination of biochemical and pancreatitis findings. The evidence establishes more than a theoretical effect on triglyceride metabolism, although treatment must continue to be evaluated for long-term efficacy, tolerability and patient access.
How does severe hypertriglyceridemia differ from familial chylomicronemia syndrome?
Severe hypertriglyceridemia describes a broad clinical condition involving markedly elevated triglyceride concentrations. Potential causes include inherited abnormalities, diabetes, obesity, alcohol consumption, certain medications and other metabolic factors. Patients can have different underlying mechanisms despite presenting with similarly high laboratory values.
Familial chylomicronemia syndrome is a much rarer inherited disorder typically associated with severe dysfunction of pathways needed to clear chylomicrons. Patients can experience extremely high triglyceride levels from an early age and recurrent pancreatitis. Their condition often requires particularly strict dietary fat restriction and specialist management.
TRYNGOLZA was already approved in the United States and European Union for adults with familial chylomicronemia syndrome before the latest severe hypertriglyceridemia development. The European expansion would make treatment available to a larger and more heterogeneous population. This represents a substantial lifecycle extension for an established medicine.
Nevertheless, the two indications should not be treated as interchangeable. They involve different patient populations, potentially different baseline risks and separate clinical evidence packages. A person with elevated triglycerides does not automatically have familial chylomicronemia syndrome, and treatment eligibility depends on the applicable regulatory indication.
What safety issues remain relevant as TRYNGOLZA reaches more patients?
The CORE and CORE2 programmes showed a generally favorable tolerability profile, but several adverse reactions remain relevant. Injection-site reactions were among the commonly reported treatment-related events. Liver enzyme elevations were also observed, and the United States prescribing information identifies abnormal liver enzymes and increases in hepatic fat as potential concerns.
Liver enzyme abnormalities were more frequently reported with the 80 mg dose than the 50 mg dose. Appropriate monitoring is therefore important, particularly when initiating treatment or adjusting dosage. Persistent or clinically significant abnormalities may require interruption or modification of treatment according to the approved labeling.
Hypersensitivity reactions have also been reported with TRYNGOLZA, including reactions requiring medical intervention. Patients with a history of serious hypersensitivity to the medicine or its components should not receive it under the United States prescribing information. The full European safety requirements will depend on the final authorized product information.
Another consideration is the possibility of combining olezarsen with other lipid-lowering medicines. The proposed European indication specifically anticipates such combination treatment, meaning clinicians must consider the patient’s full medication regimen and underlying metabolic conditions. Favorable findings in controlled studies do not eliminate the need for appropriate post-authorization safety monitoring.
What does the recommendation mean for Ionis and Sobi commercially?
Ionis discovered and developed olezarsen and commercializes TRYNGOLZA in the United States. Sobi holds exclusive commercialization rights outside the United States, excluding Canada and China. The partnership gives the companies separate commercial responsibilities while allowing the medicine to expand internationally.
The proposed severe hypertriglyceridemia indication represents a larger market opportunity than the original familial chylomicronemia syndrome population. Ionis and Sobi estimate that approximately two million people across Germany, France, Italy, Spain and the United Kingdom live with triglyceride levels of at least 500 mg/dL. Of those, approximately 700,000 are estimated to have levels of at least 880 mg/dL.
These figures describe potential disease prevalence rather than the number of patients who will necessarily receive treatment. Diagnosis, existing therapy, medical eligibility, reimbursement and physician preference will influence actual uptake. A European Commission approval would also be followed by country-specific market access procedures.
Sobi’s established rare disease commercial infrastructure may support the launch, while Ionis can continue developing the United States franchise. However, the October announcement does not disclose a European price, new revenue guidance or a specific commercial launch date. Future sales remain contingent on final authorization and successful market access.
What will determine TRYNGOLZA’s next European milestone?
The immediate regulatory milestone is the European Commission’s decision, expected in the fourth quarter of 2026. A favorable outcome would establish the final expanded indication and allow commercialization within the authorized framework. The exact wording of the approved label will be important, particularly the triglyceride threshold, background treatment requirements and applicable safety precautions.
Following authorization, physicians will need to determine which patients remain at substantial risk despite existing lipid management. The availability of an RNA-targeted therapy with demonstrated triglyceride and pancreatitis effects could provide an additional option for those meeting the indication. Nevertheless, cost, access and long-term experience will influence treatment decisions.
The CHMP recommendation is supported by a substantial randomized clinical programme involving more than 1,000 participants. Its most important findings include meaningful triglyceride reduction and fewer adjudicated acute pancreatitis events, addressing both biochemical and clinical aspects of the disease.
For Ionis and Sobi, the October 2026 decision brings TRYNGOLZA closer to a substantially broader European market. The important qualification is that the proposed EU indication remains narrower than the existing United States indication and has not yet received final European Commission approval. The next phase will determine whether the clinical evidence can translate into accessible treatment for patients at particularly high risk of pancreatitis.
